Navigation Links
Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010
Date:8/5/2010

NEWTON, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today the Company will release second quarter 2010 financial results on Tuesday, August 10, 2010, at 8:30am ET.

(Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO )

Michael C. Ferrara, President and Chief Executive Officer, and Peter F. Byczko, Vice President of Finance and Chief Accounting Officer, will host a conference call and live audio webcast.

Participants are invited to attend the call by visiting www.microfluidicscorp.com/investors and clicking on the webcast link, or by dialing 866.730.5767 (within the United States) or +1 857.350.1591 (outside the United States). The passcode is 17982013.

A replay will be available for one week beginning approximately two hours after the live call. To access the replay, dial 888.286.8010 (within the United States) or +1 617.801.6888 (outside the United States). The passcode is 45623626.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture and revolving line of credit; our history of losses, which includes net losses in four of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including health care and those regulating the exportation of goods; and general economic and business conditions, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" in our annual report on Form 10-K and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this presentation, whether as a result of new information, future events or otherwise.

ABOUT MICROFLUIDICS INTERNATIONAL CORPORATION

Microfluidics International Corporation (OTC Bulletin Board: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company's headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.

By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visit www.microfluidicscorp.com.


'/>"/>
SOURCE Microfluidics International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Microfluidics Announces Two New Board Members
2. Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results
3. Microfluidics International Corporation to Report Fourth Quarter and Year-end 2009 Financial Results on February 23, 2010
4. Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada
5. Chindex International to Report First Quarter 2011 Financial Results
6. Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International
7. Airline Passenger Experience Association Teams Up With ORBIS International in Their Fight Against Avoidable Blindness
8. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
9. New Edition of Guidelines for Involving Communities in HIV Prevention Research Released at International AIDS Conference
10. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
11. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat ... pilot a program for CleverCap LITE, a technology designed ... strives to deliver innovative health technology solutions and services ... CleverCap LITE offers medication ... high-tech bottle cover: ...
(Date:7/26/2017)... Fla. , July 26, 2017 Sancilio ... enrollment of our clinical trial evaluating Altemia TM , ... Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT ... evaluate the efficacy and safety of Altemia TM ... is conducted under US IND 125274. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy ... , Students who successfully complete the seven-week long Patient Care Academy are eligible ... The average starting salary for a CNA in Kalamazoo is $24,428.* , As a ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Greenfield Advisors is ... in the U.S. for the second year in a row. The Inc. 5000 list ... three years. , “To be on the list once is a great accomplishment, but ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test Now® is thrilled ... on the newly released, 36th annual Inc. 5000 , the most prestigious compilation ... most successful companies within the American economy’s most dynamic segment — its independent small ...
(Date:8/16/2017)... ... 2017 , ... In a recent survey, eighty-two percent of women reported having ... cellulite can't always be eliminated by diet and exercise alone, and now for the ... nationwide. Dr. Kenneth Rothaus has recently added Cellulaze™ to his practice in ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Maury Regional Health ... and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making ... the guesswork out of a needle stick and more importantly, helps our staff members ...
Breaking Medicine News(10 mins):